Curavit Clinical Research Launches DEI Planning Toolkit
Virtual CRO seeks to help life sciences companies meet new federal guidelines for diversity, equity, and inclusion in clinical trials.
Curavit Clinical Research has announced its Inclusivity, Diversity, and Equity in Action (IDEA) toolkit. IDEA is a clinical trial planning and support service designed to help clinical trial sponsors navigate challenges in developing and executing diversity action plans, now required by law for most clinical trials in the United States. Curavit's IDEA toolkit delivers support across five key functional areas:
- Preliminary Situational Analysis
- DEI Implementation Strategy
- Content Review
- Continuous Check-Ins
- Ongoing Optimization
Two early adopters of Curavit's new service offering have leveraged planning templates to ensure that they were familiar with the underrepresented patient populations that would be important to include in the trial, to compile effective strategies to recruit diverse groups of patients for enrollment, and to identify potential sites and investigators already engaged with the desired patient populations.
Reference
Curavit Clinical Research Launches First Clinical Trial DEI Planning Toolkit. (2023, June 21). Cision PR Newswire.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
